CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements

Warfarin continues to be the mainstay therapy for preventing thrombus formation. Although pharmacogenetic algorithms have shown higher predictability of the optimal warfarin dose and lower occurrence of bleeding episodes, they often do not include ethno-specific genetic variants relevant to non-Euro...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Pharmacogenomics
Autores principales: Claudio-Campos, Karla I, González-Santiago, Pablo, Renta, Jessica Y, Rodríguez, Jovaniel, Carrasquillo, Kelvin, Gaedigk, Andrea, Roche, Abiel, Ducongé, Jorge
Formato: Artigo
Lenguaje:Inglês
Publicado: Future Medicine Ltd 2019
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6479273/
https://ncbi.nlm.nih.gov/pubmed/30518301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/pgs-2018-0143
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares